AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Emma Cartmell Joins the Board of Directors for CherryCircle Software

March 19, 2019

AUSTIN, Texas--(BUSINESS WIRE)--Mar 19, 2019--CherryCircle, a software company developing the QbDVisionTMsoftware platform to accelerate pharmaceutical manufacturing process development, announced the appointment of Emma Cartmell to its board of directors. Cartmell, a renowned healthcare industry advisor and investor, will help shepherd the company through a new stage of strategy and growth followingits recent Series Seed investment round.

“CherryCircle’s QbDVision solution is the type of innovation the pharmaceutical industry needs,” said Cartmell. “I believe in their vision to reduce the amount of time and expense it takes to bring drugs and medical devices to market and this team has the experience to make it happen.”

The former Chief Operating Officer for NantHealth, Cartmell is currently angel investing and advising health tech companies who have affordable, high impact, global solutions. Cartmell also serves on the boards of the following companies and industry associations: HIMSS North America (non-profit), Austin Healthcare Council (non-profit), Morgan Stanley’s Equity Expansion Fund and multiple leading healthcare companies, including Medsphere, B.Well, Care.Coach and Accordion Health (acquired in 2017). As a founding partner in Exsede Healthcare Consulting, she guided emerging technology companies focused on precision medicine, health analytics, information technology, and wellness through processes that included capital acquisition, growth strategy creation, and partnership development.

In 2013, Ms. Cartmell was appointed as an advisor to both the U.S. and British governments on healthcare technology trade and investment, and she presents regularly at Health DataPalooza, ATA and HIMSS on the international venture capital market for digital health. In 2017 Ms. Cartmell was awarded the John. A Page Outstanding Service Award at HIMSS17 for her leadership in HIMSS and the Healthcare Industry. She is a native of the UK and a resident of Austin, Texas.

“We are beyond excited to welcome Emma to our board of directors,” said Yash Sabharwal, President and CEO, CherryCircle Software. “The depth and breadth of her knowledge and experience will be invaluable as we seek to change the way the pharma industry thinks about the manufacturing lifecycle. She brings strategic insight that will be critical to the success of our mission in an industry undergoing transformation.”

About CherryCircle Software, Inc.

CherryCircle Software, Inc. builds cloud-based solutions that help companies manufacture the highest quality drugs and medical devices reducing the development time and increasing the availability of essential therapies for patients. Its flagship product, QbDVision TM, provides the pharmaceutical industry with simple, but powerful, tools to facilitate robust manufacturing process development powered by innovation and automation, driven by data and science, and enabled by people under the frameworks of quality-by-design (QbD) and data integrity-by-design (DIbD). Started in 2016 by pharmaceutical manufacturing and quality experts, CherryCircle is headquartered in Austin, Texas and is an active member of the International Society for Pharmaceutical Engineering (ISPE). For more information, visit www.cherrycirclesoftware.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190319005061/en/

CONTACT: CherryCircle

Luke Guerrero

SVP Operations

luke@qbdvision.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL

SOURCE: CherryCircle Software, Inc.

Copyright Business Wire 2019.

PUB: 03/19/2019 08:00 AM/DISC: 03/19/2019 08:00 AM

http://www.businesswire.com/news/home/20190319005061/en